NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs from nets results Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Ruszniewski presents the results from a multi-centre randomised international trial of 177Lu-DOTATATE, at a press conference at ECC 2015.nnResults of this international, multicentre, randomised, open-label trial showed that the radiolabeled somatostatin analogue 177Lutetium-DOTATATE produced a significant improvement in progression-free survival when compared to octreotide LAR in patients with mid-gut neuroendocrine tumours.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)